Drug Trial Radar · NCT00255099
TMC125-C216: A Phase III Study to Investigate the Efficacy, Tolerability and Safety of TMC125 as Part of an Antiretroviral Regimen, Including TMC114/Ritonavir and an Investigator-selected Optimized Background, in HIV-1 Infected Patients With Limited to no Treatment Options.
Last checked: Nov 19, 2026Latest source record: Jun 15, 2011 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
593
Actual
Start
Dec 2005
Primary completion
Jan 2007
Study completion Jul 2008
Sponsor
- Lead sponsor
- Tibotec Pharmaceuticals, IrelandIndustry
- Sponsor type
- Industry
- First posted
- Nov 17, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is research with the goal of evaluating the effect of TMC125 (a non-nucleoside reverse transcriptase inhibitor) on slowing down the growth of the HIV virus. The study will also investigate whether this new medication is well tolerated, and to further confirm that the medication is safe to be used
Conditions
- HIV
Interventions
TMC125Drug
2 x 100 mg tablets b.i.d. / 96 weeks
PlaceboDrug
2 tablets b.i.d. / 96 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Evaluation of efficacy, tolerability and safety of TMC125 as part of an antiretroviral therapy containing TMC114/ritonavir and an investigator selected optimized background regimen.
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.